cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.25377/sussex.21065194.v1
title: Reflections on working with the Levenshulme girl's group

description: In 2019-2020 the ESRC funded 'Reanimating data: experiments with people, places and archives'. Part of the project involved staging a series of reanimations using data from interviews with young women from Manchester, conducted thirty years previously as part of the Women, Risk and AIDS Project (WRAP 1988-1990). Each reanimation involved a collaboration between young women, educators and researchers and used creative methods to explore the WRAP data and bring it to life in new ways.   
<br>
Ali Ronan, historian and former youth worker, shares her reflective field notes on working with the Levenshulme girl's group to 'reanimate' some of the Women, Risk & AIDS Project interviews. There are also reflections from researcher Ester McGeeney who joined the group at Levenshulme Youth Project for a couple of sessions. They talk about some of the opportunities and challenges of working with the WRAP data with young women and of youth work in general. This is a useful resource for youth workers, Relationships and Sex educators and youth researchers.
DOI: 10.34740/kaggle/dsv/7561613
title: YouTube Trending Video Dataset (updated daily)
DOI: 10.6084/m9.figshare.24547207
title: A 10-m annual grazing intensity dataset in 2015-2021 for the largest temperate meadow steppe in China

description: The grazing probability dataset (2015GP-2021GP) was in GeoTIFF format named by the year corresponding to the grazing data. There are 7 years of annual grazing probability maps with 10-m spatial resolution. The value of grazing probability maps, from 0 to 1, shows the probability of a specific pixel under heavily grazed that is non-dimensional. The grazing intensity dataset (2015GI-2021GI) was in GeoTIFF format named by the year corresponding to the grazing data. It is also in 10-m resolution and has 7 years of annual grazing intensity maps. The grazing intensity maps have values of 0, 1, and 2, which present ungrazed, moderately grazed, and heavily grazed intensity levels, respectively.
DOI: 10.25377/sussex.21065026
title: A story to tell

description: In 2019-2020 the ESRC funded 'Reanimating data: experiments with people, places and archives'. Part of the project involved staging a series of reanimations using data from interviews with young women from Manchester, conducted thirty years previously as part of the Women, Risk and AIDS Project (WRAP 1988-1990). Each reanimation involved a collaboration between young women, educators and researchers and used creative methods to explore the WRAP data and bring it to life in new ways.   
<br>
This item is a short animated film made by Emma Okomoh at a Youth Project in Manchester with support from Manchester Libraries. The film is a response to extracts from an interview with Tonya (AMB18) about her relationship with her parents and testing boundaries as a teenage young woman. The audio is read by members of the Youth Project girls group and is adapted from the original interview transcript. Emma says that this is Tonya's story and also her story.   
<br>
The item also includes a transcript from an interview with Emma about the film, her participation in the project and issues of race, generation, gender and community.
DOI: 10.25377/sussex.21065026.v1
title: A story to tell

description: In 2019-2020 the ESRC funded 'Reanimating data: experiments with people, places and archives'. Part of the project involved staging a series of reanimations using data from interviews with young women from Manchester, conducted thirty years previously as part of the Women, Risk and AIDS Project (WRAP 1988-1990). Each reanimation involved a collaboration between young women, educators and researchers and used creative methods to explore the WRAP data and bring it to life in new ways.   
<br>
This item is a short animated film made by Emma Okomoh at a Youth Project in Manchester with support from Manchester Libraries. The film is a response to extracts from an interview with Tonya (AMB18) about her relationship with her parents and testing boundaries as a teenage young woman. The audio is read by members of the Youth Project girls group and is adapted from the original interview transcript. Emma says that this is Tonya's story and also her story.   
<br>
The item also includes a transcript from an interview with Emma about the film, her participation in the project and issues of race, generation, gender and community.
DOI: 10.24403/jp.1318608
title: Der Ranunculus auricomus - Komplex in Thüringen : I. Gefährdete endemische und verkannte Arten / Franz-G. Dunkel
DOI: 10.24403/jp.1318609
title: Sambucus racemosa ˣ S. nigra - neu für Deutschland / Peter Gutte
DOI: 10.24403/jp.1318611
title: Die Moosgesellschaften des geplanten Naturschutzgebietes „Eingefallener Berg“ bei Themar : 107. Beitrag zur Moosvegetation Thüringens / Rolf Marstaller
DOI: 10.6084/m9.figshare.25075547.v1
title: Supplementary data: Treatment patterns and economic burden of bacterial vaginosis among commercially insured women in the USA

description: <b>These are peer-reviewed supplementary tables for the article '</b><b>Treatment patterns and economic burden of bacterial vaginosis among commercially insured women in the USA</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><br><b>Supplementary Table 1:</b> ICD-10 codes for other gynecological (GYN) conditions<b>Supplementary Table 2:</b> Other GYN condition associated HCRU and direct costs (2021 USD) per patient per year during the follow-up period, overall and by treatment course (TC)<b>Aim:</b> Bacterial vaginosis (BV) is a common vaginal dysbiosis associated with adverse clinical sequelae, most notably, increased risk of sexually transmitted infections (STIs). The aims of this study were to estimate the frequency of BV recurrence, treatment patterns, other gynecological (GYN) conditions, and the associated healthcare resource utilization (HCRU) and costs among commercially insured patients in the USA. <b>Patients & methods:</b> Female patients aged 12–49 years with an incident vaginitis diagnosis and ≥1 pharmacy claim for a BV medication (fungal treatment only excluded) were selected from the Merative™ MarketScan commercial database (2017–2020). During a minimum 12-month follow-up, additional treatment courses, treatment patterns, frequency of other GYN conditions, and HCRU and costs were assessed. Generalized linear models were used to identify baseline predictors of total all-cause healthcare costs and number of treatment courses. <b>Results:</b> The study population included 140,826 patients (mean age: 31.5 years) with an incident vaginitis diagnosis and ≥1 BV medication claim. During the follow-up, 64.2% had 1 treatment course, 22.0% had 2, 8.1% had 3, and 5.8% had ≥4; 35.8% had a BV recurrence (≥2 BV medication claims). The most commonly prescribed BV medication was oral metronidazole (73.6%). Approximately 12% (n = 16,619) of patients had a new diagnosis of another GYN condition in the follow-up; 8.2% had a new STI, which were more common among patients with ≥4 treatment courses (12.9%). During follow up, total all-cause healthcare costs averaged $8987 per patient per year (PPPY) of which $470 was BV related. BV-related healthcare costs increased from $403 PPPY among those with 1 treatment course to $806 PPPY among thosewith≥4with nearly half the costs attributed to outpatient office visits. <b>Conclusion:</b> BV recurrence among this population represented a substantial clinical and healthcare economic burden warranting improvements in women’s healthcare.
DOI: 10.6084/m9.figshare.25075547
title: Supplementary data: Treatment patterns and economic burden of bacterial vaginosis among commercially insured women in the USA

description: <b>These are peer-reviewed supplementary tables for the article '</b><b>Treatment patterns and economic burden of bacterial vaginosis among commercially insured women in the USA</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><br><b>Supplementary Table 1:</b> ICD-10 codes for other gynecological (GYN) conditions<b>Supplementary Table 2:</b> Other GYN condition associated HCRU and direct costs (2021 USD) per patient per year during the follow-up period, overall and by treatment course (TC)<b>Aim:</b> Bacterial vaginosis (BV) is a common vaginal dysbiosis associated with adverse clinical sequelae, most notably, increased risk of sexually transmitted infections (STIs). The aims of this study were to estimate the frequency of BV recurrence, treatment patterns, other gynecological (GYN) conditions, and the associated healthcare resource utilization (HCRU) and costs among commercially insured patients in the USA. <b>Patients & methods:</b> Female patients aged 12–49 years with an incident vaginitis diagnosis and ≥1 pharmacy claim for a BV medication (fungal treatment only excluded) were selected from the Merative™ MarketScan commercial database (2017–2020). During a minimum 12-month follow-up, additional treatment courses, treatment patterns, frequency of other GYN conditions, and HCRU and costs were assessed. Generalized linear models were used to identify baseline predictors of total all-cause healthcare costs and number of treatment courses. <b>Results:</b> The study population included 140,826 patients (mean age: 31.5 years) with an incident vaginitis diagnosis and ≥1 BV medication claim. During the follow-up, 64.2% had 1 treatment course, 22.0% had 2, 8.1% had 3, and 5.8% had ≥4; 35.8% had a BV recurrence (≥2 BV medication claims). The most commonly prescribed BV medication was oral metronidazole (73.6%). Approximately 12% (n = 16,619) of patients had a new diagnosis of another GYN condition in the follow-up; 8.2% had a new STI, which were more common among patients with ≥4 treatment courses (12.9%). During follow up, total all-cause healthcare costs averaged $8987 per patient per year (PPPY) of which $470 was BV related. BV-related healthcare costs increased from $403 PPPY among those with 1 treatment course to $806 PPPY among thosewith≥4with nearly half the costs attributed to outpatient office visits. <b>Conclusion:</b> BV recurrence among this population represented a substantial clinical and healthcare economic burden warranting improvements in women’s healthcare.
DOI: 10.6084/m9.figshare.25075517
title: Supplementary data: Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data

description: <b>This is a peer-reviewed supplementary table for the article '</b><b>Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><br><b>Supplementary Table 1:</b> MG treatment definitions<b>Aim: </b>There are limited data on the clinical and economic burden of exacerbations in patients with myasthenia gravis (MG). We assessed patient clinical characteristics, treatments and healthcare resource utilization (HCRU) associated with MG exacerbation. <b>Patients & methods:</b> This was a retrospective analysis of adult patients with MG identified by commercial, Medicare or Medicaid insurance claims from the IBM MarketScan database. Eligible patients had two or more MG diagnosis codes, without evidence of exacerbation or crisis in the baseline period (12 months prior to index [first eligible MG diagnosis]). Clinical characteristics were evaluated at baseline and 12 weeks before each exacerbation. Number of exacerbations, MG treatments and HCRU costs associated with exacerbation were described during a 2-year follow-up period. <b>Results: </b>Among 9352 prevalent MG patients, 34.4% (n = 3218) experienced ≥1 exacerbation after index: commercial, 53.0% (n = 1706); Medicare, 39.4% (n = 1269); and Medicaid, 7.6% (n = 243). During follow-up, the mean (standard deviation) number of exacerbations per commercial and Medicare patient was 3.7 (7.0) and 2.7 (4.1), respectively. At least two exacerbations were experienced by approximately half of commercial and Medicare patients with ≥1 exacerbation. Mean total MGrelated healthcare costs per exacerbation ranged from $26,078 to $51,120, and from $19,903 to $49,967 for commercial and Medicare patients, respectively. AChEI use decreased in patients with multiple exacerbations, while intravenous immunoglobulin use increased with multiple exacerbations.<b> Conclusion:</b> Despite utilization of current treatments for MG,MG exacerbations are associated with a high clinical and economic burden in both commercial and Medicare patients. Additional treatment options and improved disease management may help to reduce exacerbations and disease burden.
DOI: 10.6084/m9.figshare.25075517.v1
title: Supplementary data: Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data

description: <b>This is a peer-reviewed supplementary table for the article '</b><b>Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: a retrospective analysis of claims data</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><br><b>Supplementary Table 1:</b> MG treatment definitions<b>Aim: </b>There are limited data on the clinical and economic burden of exacerbations in patients with myasthenia gravis (MG). We assessed patient clinical characteristics, treatments and healthcare resource utilization (HCRU) associated with MG exacerbation. <b>Patients & methods:</b> This was a retrospective analysis of adult patients with MG identified by commercial, Medicare or Medicaid insurance claims from the IBM MarketScan database. Eligible patients had two or more MG diagnosis codes, without evidence of exacerbation or crisis in the baseline period (12 months prior to index [first eligible MG diagnosis]). Clinical characteristics were evaluated at baseline and 12 weeks before each exacerbation. Number of exacerbations, MG treatments and HCRU costs associated with exacerbation were described during a 2-year follow-up period. <b>Results: </b>Among 9352 prevalent MG patients, 34.4% (n = 3218) experienced ≥1 exacerbation after index: commercial, 53.0% (n = 1706); Medicare, 39.4% (n = 1269); and Medicaid, 7.6% (n = 243). During follow-up, the mean (standard deviation) number of exacerbations per commercial and Medicare patient was 3.7 (7.0) and 2.7 (4.1), respectively. At least two exacerbations were experienced by approximately half of commercial and Medicare patients with ≥1 exacerbation. Mean total MGrelated healthcare costs per exacerbation ranged from $26,078 to $51,120, and from $19,903 to $49,967 for commercial and Medicare patients, respectively. AChEI use decreased in patients with multiple exacerbations, while intravenous immunoglobulin use increased with multiple exacerbations.<b> Conclusion:</b> Despite utilization of current treatments for MG,MG exacerbations are associated with a high clinical and economic burden in both commercial and Medicare patients. Additional treatment options and improved disease management may help to reduce exacerbations and disease burden.
DOI: 10.6084/m9.figshare.25075460
title: Supplementary tables: Gastrointestinal manifestations in pediatric and adult patients with Rett syndrome: an analysis of US claims and physician survey data

description: <b>These are peer-reviewed supplementary tables for the article '</b><b>Gastrointestinal manifestations in pediatric and adult patients with Rett syndrome: an analysis of US claims and physician survey data</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><br><b>Supplementary Table 1:</b> ICD-10-CM Codes for GI Manifestations<b>Supplementary Table 2:</b> CPT Codes for MECP2 Genetic Testing<b>Supplementary Table 3:</b> ICD-10-CM Codes for Quan-Charlson Comorbidity Index<b>Supplementary Table 4:</b> ICD-10-CM Codes for Differential Diagnosis of RTTAim: Patients with Rett syndrome (RTT) experience gastrointestinal (GI) manifestations. This study aimed to describe the prevalence of GI manifestations and the associated medical costs in patients with RTT in the USA. Patients & Methods: The study combined an insurance claims database analysis with a survey of 100 physicians experienced in RTT management. Results: GI manifestations affected 43.0% of 5940 patients, with increased prevalence in pediatric patients (45.6%) relative to adult patients (40.2%). Annualized mean medical cost of managing GI manifestations was $4473. Only 5.9–8.2% of neurologists and pediatricians ranked GI symptom management among the five most important treatment goals. Conclusion: Patients with RTT experience a high burden of GI manifestations, which translate to considerable medical costs. Importantly, the prevalence of GI manifestations was likely underestimated in this study, as only those symptoms which resulted in a healthcare encounter were captured.<br>
DOI: 10.6084/m9.figshare.25075460.v1
title: Supplementary tables: Gastrointestinal manifestations in pediatric and adult patients with Rett syndrome: an analysis of US claims and physician survey data

description: <b>These are peer-reviewed supplementary tables for the article '</b><b>Gastrointestinal manifestations in pediatric and adult patients with Rett syndrome: an analysis of US claims and physician survey data</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b><br><b>Supplementary Table 1:</b> ICD-10-CM Codes for GI Manifestations<b>Supplementary Table 2:</b> CPT Codes for MECP2 Genetic Testing<b>Supplementary Table 3:</b> ICD-10-CM Codes for Quan-Charlson Comorbidity Index<b>Supplementary Table 4:</b> ICD-10-CM Codes for Differential Diagnosis of RTTAim: Patients with Rett syndrome (RTT) experience gastrointestinal (GI) manifestations. This study aimed to describe the prevalence of GI manifestations and the associated medical costs in patients with RTT in the USA. Patients & Methods: The study combined an insurance claims database analysis with a survey of 100 physicians experienced in RTT management. Results: GI manifestations affected 43.0% of 5940 patients, with increased prevalence in pediatric patients (45.6%) relative to adult patients (40.2%). Annualized mean medical cost of managing GI manifestations was $4473. Only 5.9–8.2% of neurologists and pediatricians ranked GI symptom management among the five most important treatment goals. Conclusion: Patients with RTT experience a high burden of GI manifestations, which translate to considerable medical costs. Importantly, the prevalence of GI manifestations was likely underestimated in this study, as only those symptoms which resulted in a healthcare encounter were captured.<br>
DOI: 10.5281/zenodo.10580119
title: GRAPE_DETECTION_DATASET

description: The dataset consists of three distinct groups of RGB images, each designed for training and validation purposes. The groups were separated based on the camera sensor used to collect the data. The first set contains 151 images, with 101 for training and 50 for validation. The first group is contained in the C1 folder. These images were taken with a ZED Mini camera held by hand at a constant distance of one meter from the vineyard. The resolution varies within this set, with images available in 1024 x 1024 or 2208 x 1242 pixels. The second collection encompasses 236 RGB images, of which 155 are designated for training and 81 for validation. The second group is contained in the C2 and C3 folders. These images were taken with an Intel Realsense D435 camera, capturing shots of the grapes positioned 20 to 50 cm away from the camera. The resolution for this set is standardized at 1920 x 1080 pixels, with the camera securely mounted on one of the robot's arms. The third and final group consists of 1320 images, with 1092 allocated for training and 228 for validation. This group is splitted in the I1, I2 and I3 folders. Captured using a ZED2 camera, these images were obtained by an inspection platform located 1 meter away from the vineyard, maintaining a resolution of 1920 x 1080 pixels. Together, these diverse sets form a comprehensive RGB dataset for the development and assessment of vineyard-related algorithms. This dataset used for detecting the grapes in the images. All of the data were collected at Ktima Gerovassiliou in Epanomi, Thessaloniki.

Below, there are six separate folders with the training data (which can be merged into one) and one folder containing the validation data. Every image has a txt file containing the image's grapes annotations. The first number represents the annotation's class (0 for grape), the second and third numbers are the normalized (in the image's shape) coordinates of the grape's bounding box up left edge, and the fourth and fifth numbers are the bounding box's width and height accordingly.
DOI: 10.5281/zenodo.10580120
title: GRAPE_DETECTION_DATASET

description: The dataset consists of three distinct groups of RGB images, each designed for training and validation purposes. The groups were separated based on the camera sensor used to collect the data. The first set contains 151 images, with 101 for training and 50 for validation. The first group is contained in the C1 folder. These images were taken with a ZED Mini camera held by hand at a constant distance of one meter from the vineyard. The resolution varies within this set, with images available in 1024 x 1024 or 2208 x 1242 pixels. The second collection encompasses 236 RGB images, of which 155 are designated for training and 81 for validation. The second group is contained in the C2 and C3 folders. These images were taken with an Intel Realsense D435 camera, capturing shots of the grapes positioned 20 to 50 cm away from the camera. The resolution for this set is standardized at 1920 x 1080 pixels, with the camera securely mounted on one of the robot's arms. The third and final group consists of 1320 images, with 1092 allocated for training and 228 for validation. This group is splitted in the I1, I2 and I3 folders. Captured using a ZED2 camera, these images were obtained by an inspection platform located 1 meter away from the vineyard, maintaining a resolution of 1920 x 1080 pixels. Together, these diverse sets form a comprehensive RGB dataset for the development and assessment of vineyard-related algorithms. This dataset used for detecting the grapes in the images. All of the data were collected at Ktima Gerovassiliou in Epanomi, Thessaloniki.

Below, there are six separate folders with the training data (which can be merged into one) and one folder containing the validation data. Every image has a txt file containing the image's grapes annotations. The first number represents the annotation's class (0 for grape), the second and third numbers are the normalized (in the image's shape) coordinates of the grape's bounding box up left edge, and the fourth and fifth numbers are the bounding box's width and height accordingly.
DOI: 10.34740/kaggle/dsv/7561653
title: 📒 Meta Kaggle ported to MS SQL SERVER 2022 DB